Brief: EMA Says Would Need Neutralisation Of Variant Shot At Same Level As Original

Abitibi Metals

09/12/2021 13:22

Dec 9 (Reuters) - European Medicines Agency (EMA) Briefing: 
    * EU DRUG REGULATOR EMA SAYS DECISION ON NOVAVAX'S COVID-19
VACCINE EXPECTED BY THE END OF THE YEAR
    * EU DRUG REGULATOR EMA SAYS ADVICE ON USE OF COVID-19 PILL
PAXLOVID EXPECTED BY THE END OF THE YEAR
    * EU DRUG REGULATOR EMA SAYS GSK-VIR'S XEVUDY WILL BE
CONSIDERED
BY HUMAN MEDICINES COMMITTEE NEXT WEEK FOR THE TREATMENT OF
COVID-19 PATIENTS
    * EU DRUG REGULATOR EMA SAYS WILL BE TALKING TO COVID-19
VACCINE
MAKERS TO LOOK WHAT IS THE PLAN FOR DEVELOPMENT OF A POTENTIAL
OMICRON VARIANT VACCINE
    * EU DRUG REGULATOR EMA SAYS IN A MATTER OF THREE TO FOUR
MONTHS
WE WILL BE IN A POSITION TO APPROVE A VARIANT VACCINE FOR
OMICRON
    * EU DRUG REGULATOR EMA SAYS AS A MINIMUM, WOULD NEED
NEUTRALISATION OF NEW VARIANT VACCINE TO BE AT SAME LEVEL AS
WITH ORIGINAL COVID-19 SHOT


 ((Reuters.Briefs@thomsonreuters.com;))